- Home
- Companies
- canada nunavut
- solid tumor
Show results for
Refine by
Solid Tumor Suppliers Serving Nunavut
58 companies found
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene ...
based inMilan, ITALY
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in ...
based inGoettingen, GERMANY
We provide the essential products, technologies and expertise to produce biopharmaceuticals reliably and efficiently. In fact, Sartorius has been pioneering and setting the standards for single-use products that are currently used throughout all ...
based inFlorence, ITALY
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, ...
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is ...
based inNorcross, GEORGIA (US) (USA)
Caprico Biotechnologies, Inc. (CBI) was founded in 2013 by a group of experienced scientists with broad clinical and basic research experience in chemistry, molecular biology, and immunology. We are committed to providing a range of flow cytometry ...
The clone 528, a mouse monoclonal antibody, specifically reacts with an epitope of the ~170 kDa extracellular protein domain of human epidermal growth factor receptor or commonly known as EGFR. Physiologically EGFR is expressed in the skin, ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
ISET, Isolation by SizE of Tumor Cells, is based on the antibody-independent whole blood filtration approach for CTCs and micro-emboli isolation. The solution relies on the larger size of all types of CTCs as compared to the majority ...
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
Tissue500™ is a comprehensive genomic profiling test that detects clinically relevant mutations in 572 genes to identify a patient’s unique cancer ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
Whole transcriptome RNA sequencing allows for the analysis of fusion genes with potential clinical utility that currently cannot be detected using the limited genomic coverage of targeted NGS panels. Additionally, some clinical cancer testing labs ...
based inShanghai, CHINA
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 5 ...
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
Targeted Radionuclide Therapy (TRT) or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like cancer. Once ...
based inUppsala, SWEDEN
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help ...
The most comprehensive, high-performance protein biomarker panels available for oncology studies. The flexibility and scalability of our Olink® Explore platform can be utilized either to screen our entire library of 3072 assays, or in ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
It is a human monoclonal antibody that can be potentially used in the treatment of Hepatocellular Carcinoma, Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
Chemo-scale is an advanced non-invasive test which provides therapeutically relevant information and is based on a safe, simple, and quick blood draw. Chemo-scale™ investigates in vitro chemo-resistance in Circulating Tumor Associated Cells ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inChangning District, CHINA
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative ...